11:I[677749,["/_next/static/chunks/26vjkayxt7q_9.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/00jfqdbzcs08q.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/247y8d63escwn.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/2xy8fh9yi2ian.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/1_6bb6xkmfuk_.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/0p8w8kzp3b11o.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/18z6da0bjb32s.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/2ufp0gxx3hn3k.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/3kn8z9kxrf4rv.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA"],"ProfileSubPage"] 12:I[790161,["/_next/static/chunks/26vjkayxt7q_9.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/00jfqdbzcs08q.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/247y8d63escwn.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/2xy8fh9yi2ian.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/1_6bb6xkmfuk_.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/0p8w8kzp3b11o.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/18z6da0bjb32s.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/2ufp0gxx3hn3k.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/3kn8z9kxrf4rv.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA"],"AccessGate"] 14:I[27201,["/_next/static/chunks/1_wwd7v6xaer4.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA","/_next/static/chunks/12al-veyqkqz1.js?dpl=dpl_8enxXbU8oJJq7t2eoyESnr4SmyGA"],"IconMark"] 13:T511,

Protocols

No established protocols are available in the published literature for the combination of retatrutide and IGF-1 LR3.

Based on the evidence search, no clinical trials or peer-reviewed studies have been identified that examine the combined use of retatrutide (a GLP-1/GIP/glucagon receptor agonist) with IGF-1 LR3 (Long R3 insulin-like growth factor-1). Without published clinical data, there are no validated dosing regimens, administration schedules, or safety protocols for this combination therapy.

Individual protocols for each compound separately may exist in the literature, but the safety, efficacy, and appropriate dosing of their combined use has not been established through clinical research.

Important Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Any consideration of experimental compound combinations should only be undertaken under the direct supervision of qualified healthcare professionals who can assess individual medical history, current health status, and potential risks. The absence of clinical evidence for this combination means that safety profiles, drug interactions, and appropriate monitoring parameters are unknown.

Retatrutide + IGF-1 LR3

Member access required